Typhoid Fever Vaccines Market to Surpass US$ 884.8 Mn by 2030

Global Typhoid Fever Vaccines Market, by Vaccine Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccines, Conjugate Vaccine, and Others), by Route of Administration (Oral and Parental), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 351.4 Million in 2022 and is expected to exhibit a CAGR of 12.2% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Increasing government initiatives for rising awareness regarding typhoid vaccines and supporting access to new vaccines are expected to drive the global typhoid fever vaccines market growth. For instance, in April 2018, Gavi designated US$ 85 million to fund introduction of Typbar TCV (Bharat Biotech) vaccine in low-income countries across Africa and Asia region. Moreover, there are several typhoid conjugate vaccines present in the pipeline, which are expected to enter in market over the forecast period. In October 2017, World Health Oraganization’s Strategic Advisory Group of Experts on Immunization (SAGE) re-emphasized the importance of typhoid vaccines in low- and middle-income countries, as well as for the control of endemic typhoid. Moreover, the Typhoid Vaccine Acceleration Consortium (TyVAC), which is a partnership between University of Maryland School of Medicine, University of Oxford and PATH, is conducting clinical trials for Typbar TCV prequalified vaccine in Malawi, Nepal, and Bangladesh to further evaluate clinical efficacy and potential of the vaccine in reducing typhoid burden in these countries. Furthermore, introduction of clinically more effective typhoid vaccines in private markets (such as India) as well as internationally has driven growth of market. For instance, Vivotif (oral vaccine), clinically more effective Typhim Vi (WHO prequalified in 2011), and now Typbar TCV (first conjugate vaccine WHO prequalified in 2017) are now available in market

Global Typhoid Fever Vaccines Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

However, the COVID-19 pandemic had a negative impact on the global typhoid fever vaccines market, owing to disruption in supply chain and its possible association with the COVID-19 infection. For instance, in July 2021, according to an article published by the National Center for Biotechnology Information, a series of databases relevant to biotechnology and biomedicine, in November 2021, World Health Organization and UNICEF warned an alarming decline in the number of children receiving life-saving vaccines around the world. This is due to disruptions in the delivery and uptake of immunization services caused by the COVID-19 pandemic.

Global Typhoid Fever Vaccines Market: Key Developments

In May 2022, University of Maryland, Baltimore, carried out a study on Drug: Vaxchora and Vivotif Typhoid Oral Vaccine which is in phase 4 clinical trial study. Both vaccines used in this study are licensed by the Food and Drug Administration (FDA) for travelers to emerging economies. This study is to better understand how vaccines against typhoid fever and cholera affect the normal immune system and bacteria in the intestine.

In July 2022, International Centre for Diarrhoeal Disease Research, Bangladesh, was studying double blinded, randomized-controlled, non-inferiority trial of a typhoid conjugate vaccine, Typhocon (Vi- polysaccharide conjugated to diphtheria toxoid, Vi-DT), manufactured by a local company, Incepta Vaccine Limited. The vaccine will be tested among individuals from 6 months to 60 years of age residing in Mirpur area of Dhaka city. The Typbar-TCV (Vi-polysaccharide conjugated to tetanus toxoid, Vi-TT), manufactured by Bharat Biotech International Limited will be used as a reference vaccine in this study. Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) is in the phase 2 trial and the study is estimated to get completed in January 2023. 

Browse 26 Market Data Tables and 25 Figures spread through 177 Pages and in-depth TOC on “Global Typhoid Fever Vaccines Market”- Forecast to 2030, Global Typhoid Fever Vaccines Market, by Vaccine Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccines, Conjugate Vaccine, and Others), by Route of Administration (Oral and Parental), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/typhoid-fever-vaccines-market-2552

Moreover, increasing research and development activities for the typhoid fever vaccine is expected to drive the global typhoid fever vaccine market growth over the forecast period. For instance, on August 16 2022, Christian Medical College, Vellore, India, initiated a study on the Typhoid conjugate Vaccine. This cluster randomized trial will examine the impact of introducing TyphiBEV, a typhoid conjugate vaccine licensed in India, on the incidence of typhoid fever in a high burden urban setting in South India.

Key Takeaways of the Global Typhoid Fever Vaccines Market:

• Global typhoid fever vaccines market is expected to exhibit a CAGR of 12.2% during the forecast period due to the increasing research and development activities by key players in market, which is expected to drive the global typhoid fever vaccines market growth. For instance, in May 2021, University of Sheffield, a public research university in Sheffield in U.K. carried out a study for the host gene expression response to infection in endemic populations as a new approach to identifying patients with enteric fever and paratyphoid fever.
• North America typhoid fever vaccines market is expected to show stagnant growth over the forecast period, owing to low prevalence of typhoid in the region. For instance, according to the data published by Centers of Disease Control and Prevention (CDC) 2017, around 300 culture-confirmed cases of typhoid fever and 80 cases of paratyphoid fever caused by S. enterica serotype Paratyphi A were reported annually in the U.S.
• Major players operating in the global typhoid fever vaccines market include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium